Synapse - Vicky Makker

Results (267)

Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary

Journal Article

Finch, L.; Andres, S.; Iasonos, A.; Zhou, Q.; Girshman, J.; Chhetri-Long, R.; Green, H.; Selenica, P.; Jang, D.; O'Cearbhaill, R. E.; more...
International Journal of Gynecological Cancer (2025)

Fulltext@MSK | Save

Dose-expansion part of a phase 1b global study of E7386 plus lenvatinib in patients with hepatocellular carcinoma and other solid tumors including endometrial cancer

Meeting Abstract

Lee, J. Y.; Ryoo, B. Y.; Kim, J. W.; Cheng, A. L.; Finn, R. S.; Hasegawa, K.; Makker, V.; Kudo, M.; Miller, D. S.; Merle, P.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer

Meeting Abstract

Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53WT advanced or recurrent endometrial cancer: Follow up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Meeting Abstract

Fidalgo, J. A. P.; Vergote, I.; Hamilton, E.; Giorgi, U. D.; Gorp, T. V.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; Fariñas-Madrid, L.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)

Meeting Abstract

Lee, J. Y.; Hasegawa, K.; Kim, B. G.; Corr, B. R.; Kondo, S.; Suzuki, S.; Yunokawa, M.; Miller, D. S.; Tamai, T.; Dutta, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study

Meeting Abstract

Danska-Bidzinska, A.; Makker, V.; Salutari, V.; Ayhan, A.; Romero, I.; Levy, T.; McCormack, M.; Baurain, J. F.; Mach, P.; Cadoo, K. A.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors

Meeting Abstract

Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2

Meeting Abstract

Lee, J. Y.; Makker, V.; Oaknin, A.; Oh, D. Y.; Anoka, C.; Jung, L.; Simoes, J.; Puvvada, S. D.; Meric-Bernstam, F.
Annals of Oncology (2024)

Fulltext@MSK | Save

A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer

Meeting Abstract

Girda, E.; Makker, V.; Marth, C.; Van Gorp, T.; Mirza, M.; Shapira-Frommer, R.; Suttner, L.; Groisberg, R.; Jin, F.; O'Malley, D.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Prognostic value of aggressive histology in surgically-staged, clinically uterine-confined endometrial carcinoma

Meeting Abstract

Dagher, C.; Mueller, J.; Abu-Rustum, N.; Sonoda, Y.; Momeni-Boroujeni, A.; Makker, V.; O'Cearbhaill, R.; Alektiar, K.; Leitao, M.
Gynecologic Oncology (2024)

Fulltext@MSK | Save